Lyra Therapeutics (formerly known as 480 Biomedical) is a therapeutics company focused on the development of integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It develops LYR-210 and LYR-220, bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis. The company offers XTreo designed to enable sustained delivery of medications for many months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches.
|HQ||Watertown, MA, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (22-Oct-2021)
Closing stock price (22-Oct-2021)
Lyra Therapeutics has 58 Twitter Followers. The number of followers has increased 3.6% month over month and increased 4.1% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2005.
Who are Lyra Therapeutics key executives?
Lyra Therapeutics's key executives are Maria Palasis, Corinne Noyes and Robert Kern.
How many employees does Lyra Therapeutics have?
Lyra Therapeutics has 34 employees.
Who are Lyra Therapeutics competitors?
Competitors of Lyra Therapeutics include Intersect ENT, Wugen and oncomed.
Where is Lyra Therapeutics headquarters?
Lyra Therapeutics headquarters is located at 480 Arsenal St, Watertown.
Where are Lyra Therapeutics offices?
Lyra Therapeutics has an office in Watertown.
How many offices does Lyra Therapeutics have?
Lyra Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies